R&D Tax Incentive Received
Brisbane, Jan 18, 2018 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) is pleased to announce that it has received $1,230,329 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme.
The refund is from Anatara's 2016-2017 research activities and reflects a period of significant investment into the Company's lead product, Detach(R), for the control of gastrointestinal disease in pigs, as well as activities designed to progress Anatara's human therapeutics pipeline.
Anatara's Chairman and CEO, Dr Mel Bridges said, "The 2016-2017 period was an important one for Anatara as we focused on moving Detach closer to market and prepared to expand our program into human applications. The R&D tax incentive provides an important source of non-dilutive funding and enables the Company to remain well funded as we progress our commercialisation activities."
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
